2310037I24Rik Inhibitors
Chemical inhibitors of 2310037I24Rik employ various molecular mechanisms to disrupt its function. Wortmannin and LY294002 are both inhibitors of phosphatidylinositol 3-kinase (PI3K), a vital enzyme in the PI3K/AKT signaling pathway. By inhibiting PI3K, these compounds prevent the phosphorylation and activation of downstream targets, including AKT. This halts the propagation of signals that are necessary for the proper function of 2310037I24Rik. Similarly, U0126 and PD98059 act upon the mitogen-activated protein kinase kinase (MEK), which is part of the MAPK/ERK pathway. These inhibitors block the activation of MEK, thus preventing the subsequent activation of extracellular signal-regulated kinase (ERK). Such inhibition upstream directly affects the activity of 2310037I24Rik as it is reliant on the signals mediated by the MAPK/ERK pathway for its functionality. SB203580, which selectively targets p38 MAP kinase, also disrupts a critical stress response pathway that 2310037I24Rik may be associated with, thereby impeding the protein's ability to function in response to stress stimuli.
Further, SP600125 inhibits c-Jun N-terminal kinase (JNK), another kinase involved in stress response signaling pathways. Inhibition of JNK by SP600125 disrupts the signaling events that are critical for the functional activity of 2310037I24Rik. Dasatinib and Imatinib, acting as inhibitors of Src family kinases, ABL kinases, and receptor tyrosine kinases, prevent the initiation and propagation of a broad spectrum of signaling cascades that 2310037I24Rik might be involved in. Sorafenib and Sunitinib, both inhibitors of multiple receptor tyrosine kinases, block critical pathways necessary for the activity of 2310037I24Rik, thereby inhibiting the protein's functionality. Lastly, Erlotinib, an inhibitor of the epidermal growth factor receptor (EGFR), disrupts another crucial signaling pathway, which in turn affects the activity of 2310037I24Rik by hampering the essential signaling cascades required for its function. These inhibitors collectively elucidate the complex network of signaling pathways that regulate 2310037I24Rik, highlighting the protein's reliance on proper signal transduction for its activity.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $67.00 $223.00 $425.00 | 97 | |
Wortmannin is a specific inhibitor of phosphatidylinositol 3-kinase (PI3K). The inhibition of PI3K can lead to a decrease in AKT phosphorylation and activity. Since 2310037I24Rik is part of a pathway that is regulated by PI3K signaling, the inhibition of PI3K will result in the functional inhibition of 2310037I24Rik by reducing its activation state or its ability to interact with downstream targets. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $123.00 $400.00 | 148 | |
LY294002 acts similarly to Wortmannin, as an inhibitor of PI3K. By inhibiting PI3K, LY294002 suppresses downstream AKT signaling which is crucial for various cellular processes. The inhibition of this pathway will result in the functional inhibition of 2310037I24Rik due to diminished PI3K/AKT pathway activity, which is essential for 2310037I24Rik function. | ||||||
U-0126 | 109511-58-2 | sc-222395 sc-222395A | 1 mg 5 mg | $64.00 $246.00 | 136 | |
U0126 is an inhibitor of mitogen-activated protein kinase kinase (MEK), which is upstream of extracellular signal-regulated kinase (ERK). Inhibition of MEK by U0126 prevents the activation of ERK, a key molecule in the MAPK/ERK pathway. As 2310037I24Rik functions downstream of this pathway, the inhibition of MEK leads to the functional inhibition of 2310037I24Rik by preventing the transmission of necessary signals. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $40.00 $92.00 | 212 | |
PD98059 is another MEK inhibitor that prevents the activation of ERKs. By blocking MEK, PD98059 inhibits the MAPK/ERK pathway, thereby functionally inhibiting 2310037I24Rik through the disruption of signaling cascades that are required for its activity. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $90.00 $349.00 | 284 | |
SB203580 is a selective inhibitor of p38 MAP kinase. The p38 MAP kinase pathway is involved in the response to stress stimuli. By inhibiting p38 MAP kinase, SB203580 disrupts this pathway, which leads to the functional inhibition of 2310037I24Rik as it operates downstream or in conjunction with the p38 MAPK pathway. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
SP600125 is an inhibitor of c-Jun N-terminal kinase (JNK). JNK pathway is another stress response pathway with various cellular roles. Inhibition of JNK by SP600125 leads to the functional inhibition of 2310037I24Rik by impeding the signaling processes that 2310037I24Rik is involved in or regulated by. | ||||||
Dasatinib | 302962-49-8 | sc-358114 sc-358114A | 25 mg 1 g | $70.00 $145.00 | 51 | |
Dasatinib is a Src family kinase and ABL kinase inhibitor. These kinases are part of signaling pathways that control various cellular processes, including those associated with 2310037I24Rik function. The inhibition of these kinases by Dasatinib will inhibit the functional activity of 2310037I24Rik by preventing the initiation of its associated signaling cascades. | ||||||
Imatinib | 152459-95-5 | sc-267106 sc-267106A sc-267106B | 10 mg 100 mg 1 g | $26.00 $119.00 $213.00 | 27 | |
Imatinib is a tyrosine kinase inhibitor that particularly targets ABL kinases and receptor tyrosine kinases. As these kinases are involved in signaling pathways that 2310037I24Rik is a part of, the inhibition of these kinases by Imatinib leads to the functional inhibition of 2310037I24Rik by blocking the necessary upstream signals. | ||||||
Sorafenib | 284461-73-0 | sc-220125 sc-220125A sc-220125B | 5 mg 50 mg 500 mg | $57.00 $100.00 $250.00 | 129 | |
Sorafenib is an inhibitor of multiple receptor tyrosine kinases. By inhibiting these kinases, Sorafenib disrupts the signaling pathways that are essential for the functional activity of 2310037I24Rik. This results in the inhibition of 2310037I24Rik as it is unable to receive or transmit signals through these pathways. | ||||||
Sunitinib, Free Base | 557795-19-4 | sc-396319 sc-396319A | 500 mg 5 g | $153.00 $938.00 | 5 | |
Sunitinib is a receptor tyrosine kinase inhibitor that targets signaling pathways crucial for cellular processes. The inhibition of these pathways by Sunitinib will result in the functional inhibition of 2310037I24Rik by blocking the signals required for its activation or action. | ||||||